PMID- 37119005
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231103
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 19
IP  - 8
DP  - 2023 Jul-Dec
TI  - A prospective single-arm study on the efficacy and safety of short-course oral 
      corticosteroids followed by topical corticosteroids in patients with severe 
      chronic rhinosinusitis with nasal polyps.
PG  - 1029-1039
LID - 10.1080/1744666X.2023.2209724 [doi]
AB  - BACKGROUND: Little evidence exists regarding an integrated multidimensional 
      evaluation methodology to analyze the within-patient effects of medical treatment 
      for chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to use an 
      integrated evaluation model to analyze the effects of short-course oral 
      corticosteroid (OCS) followed by intranasal corticosteroid spray (INCS) therapy 
      in patients with severe CRSwNP. METHODS: In all, 32 patients with severe CRSwNP 
      received oral methylprednisolone for three weeks followed by intranasal 
      budesonide spray for nine weeks in this prospective single-arm study. An 
      evaluation model integrating the concepts of the core outcome set (COS), clinical 
      control and minimum clinically important difference (MCID) was longitudinally 
      evaluated. RESULTS: All uncontrolled patients at baseline showed similar 
      progressive improvements from baseline and more than 1 MCID response across core 
      outcomes during the OCS period, with severe CRSwNP being partly controlled in 31 
      (96.9%) patients and uncontrolled in 1 (3.1%) patient at 3 weeks. During the 
      subsequent INCS period, 14 (43.8%) patients gradually deteriorated to an 
      uncontrolled status at 12 weeks, whereas 18 (56.2%) exhibited partly controlled 
      CRSwNP until 12 weeks. CONCLUSIONS: In more than half of the patients, severe 
      CRSwNP was partly controlled with the initial OCS followed by INCS therapy. An 
      integrated evaluation model was used to facilitate the comprehensive evaluation 
      of within-patient response, especially in patients with different responses to 
      the same treatment. TRIAL REGISTRATION: ChiCTR1900024287.
FAU - Shao, Shan
AU  - Shao S
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, 
      Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China.
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Youan Hospital, 
      Capital Medical University, Beijing 100069, China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, 
      Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China.
AD  - Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases 
      (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal 
      diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of 
      Education of China) of Capital Medical University, Beijing 100005, China.
FAU - Zhang, Nan
AU  - Zhang N
AD  - Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent 
      University Hospital, 9000 Ghent, Belgium.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, 
      Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China.
AD  - Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases 
      (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal 
      diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of 
      Education of China) of Capital Medical University, Beijing 100005, China.
FAU - Zhang, Xuelian
AU  - Zhang X
AD  - Department of Endocrinology, Beijing Tongren Hospital, Capital Medical 
      University, Beijing 10073, China.
FAU - Sima, Yutong
AU  - Sima Y
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, 
      Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China.
AD  - Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases 
      (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal 
      diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of 
      Education of China) of Capital Medical University, Beijing 100005, China.
FAU - Wang, Ping
AU  - Wang P
AD  - Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases 
      (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal 
      diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of 
      Education of China) of Capital Medical University, Beijing 100005, China.
FAU - Xu, Yuan
AU  - Xu Y
AD  - Departments of Oncology, Community Health Sciences, and Surgery, Cumming School 
      of Medicine, and The Center for Health Informatics, University of Calgary, 
      Calgary, Alberta, Canada.
FAU - Wang, Tie
AU  - Wang T
AD  - MIID Snyder Institute for Chronic Diseases, Cumming School of Medicine, 
      University of Calgary, Calgary, Alberta, Canada.
FAU - Bao, Shiping
AU  - Bao S
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Youan Hospital, 
      Capital Medical University, Beijing 100069, China.
FAU - Cao, Yu
AU  - Cao Y
AD  - Department of Epidemiology research, Beijing Youan Hospital, Capital Medical 
      University, Beijing 100069, China.
FAU - Wang, Xiangdong
AU  - Wang X
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, 
      Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China.
AD  - Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases 
      (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal 
      diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of 
      Education of China) of Capital Medical University, Beijing 100005, China.
FAU - Zhang, Luo
AU  - Zhang L
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, 
      Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China.
AD  - Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases 
      (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal 
      diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of 
      Education of China) of Capital Medical University, Beijing 100005, China.
FAU - Bachert, Claus
AU  - Bachert C
AD  - Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent 
      University Hospital, 9000 Ghent, Belgium.
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital of 
      Munster, Munster, Germany.
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, Guangdong, China.
LA  - eng
SI  - ChiCTR/ChiCTR1900024287
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230505
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Dermatologic Agents)
SB  - IM
MH  - Humans
MH  - *Nasal Polyps/drug therapy
MH  - Prospective Studies
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - *Sinusitis/drug therapy
MH  - Administration, Intranasal
MH  - *Dermatologic Agents/therapeutic use
MH  - Chronic Disease
MH  - *Rhinitis/drug therapy
OTO - NOTNLM
OT  - Chronic rhinosinusitis
OT  - glucocorticoids
OT  - minimal clinically important difference
OT  - nasal polyps
OT  - outcome measures
EDAT- 2023/04/29 19:42
MHDA- 2023/04/29 19:43
CRDT- 2023/04/29 05:25
PHST- 2023/04/29 19:43 [medline]
PHST- 2023/04/29 19:42 [pubmed]
PHST- 2023/04/29 05:25 [entrez]
AID - 10.1080/1744666X.2023.2209724 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2023 Jul-Dec;19(8):1029-1039. doi: 
      10.1080/1744666X.2023.2209724. Epub 2023 May 5.